Oh the irony: Iron as a cancer cause or cure?

Biomaterials

Volumn 32, Issue 35, 2011, Pages 9155-9158

  Foy, Susan P ^a   Labhasetwar, Vinod ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Cancer therapy; Iron; Magnetic nanoparticles; Oxidative stress; Reactive oxygen species

Indexed keywords

CANCER CELLS; CANCER DIAGNOSIS; CANCER THERAPY; ENHANCED CONTRAST; FENTON REACTIONS; HIGH DEMAND; HIGH DOSE; MAGNETIC DRUG TARGETING; MAGNETIC HYPERTHERMIA; MAGNETIC NANOPARTICLES; REACTIVE OXYGEN SPECIES; TUMOR CELLS; TUMOR GROWTH;

CELL DEATH; CURING; DISEASES; DRUG DELIVERY; IRON; NANOMAGNETICS; NANOPARTICLES; ONCOLOGY; OXIDATIVE STRESS; OXYGEN; TUMORS;

IRON OXIDES;

DEFEROXAMINE MESYLATE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROPORTIN; FERROUS ION; HYDROXYL RADICAL; IRON; IRON CHELATING AGENT; IRON DEXTRAN; IRON OXIDE; IRON SORBITEX; MONOFER; REACTIVE OXYGEN METABOLITE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENICITY; CARDIOTOXICITY; CYTOTOXICITY; DNA DAMAGE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FENTON REACTION; GENE TARGETING; GLIOBLASTOMA; HUMAN; HYPERTHERMIA; IRON CHELATION; IRON DEPLETION; IRON OVERLOAD; IRON STORAGE; IRON THERAPY; IRON TRANSPORT; MAGNETIC FIELD; MALIGNANT TRANSFORMATION; MELANOMA; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SARCOMA; SINGLE DRUG DOSE; TUMOR ABLATION;

ANIMALS; HUMANS; HYDROGEN PEROXIDE; IRON; MAGNETIC PHENOMENA; NANOPARTICLES; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 80053612079     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.047     Document Type: Article

References (36)

1. Fang J., Seki T., Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 2009, 61:290-302.
2. Stevens R.G., Graubard B.I., Micozzi M.S., Neriishi K., Blumberg B.S. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994, 56:364-369.
3. Bae Y.J., Yeon J.Y., Sung C.J., Kim H.S., Sung M.K. Dietary intake and serum levels of iron in relation to oxidative stress in breast cancer patients. J Clin Biochem Nutr 2009, 45:355-360.
4. Moore A.B., Shannon J., Chen C., Lampe J.W., Ray R.M., Lewis S.K., et al. Dietary and stored iron as predictors of breast cancer risk: a nested case-control study in Shanghai. Int J Cancer 2009, 125:1110-1117.
5. Osborne N.J., Gurrin L.C., Allen K.J., Constantine C.C., Delatycki M.B., McLaren C.E., et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010, 51:1311-1318.
6. McCarty M.F., Barroso-Aranda J., Contreras F. Oxidative stress therapy for solid tumors - a proposal. Med Hypotheses 2010, 74:1052-1054.
7. Jiang X.P., Elliott R.L., Head J.F. Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res 2010, 30:759-765.
8. Hoke E.M., Maylock C.A., Shacter E. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic Biol Med 2005, 39:403-411.
9. Buss J.L., Greene B.T., Turner J., Torti F.M., Torti S.V. Iron chelators in cancer chemotherapy. Curr Top Med Chem 2004, 4:1623-1635.
10. Kiessling M.K., Klemke C.D., Kaminski M.M., Galani I.E., Krammer P.H., Gulow K. Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma. Cancer Res 2009, 69:2365-2374.
11. Poljak-Blazi M., Stancic-Rokotov D., Ferle-Vidovic A. Inhibitory effect of iron on melanoma B16 growth. Period Biol 1985, 87:17-21.
12. Jain T.K., Richey J., Strand M., Leslie-Pelecky D.L., Flask C.A., Labhasetwar V. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials 2008, 29:4012-4021.
13. Yallapu M.M., Othman S.F., Curtis E.T., Gupta B.K., Jaggi M., Chauhan S.C. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials 2011, 32:1890-1905.
14. Lubbe A.S., Bergemann C., Huhnt W., Fricke T., Riess H., Brock J.W., et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 1996, 56:4694-4701.
15. Balivada S., Rachakatla R.S., Wang H., Samarakoon T.N., Dani R.K., Pyle M., et al. A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer 2010, 10:119.
16. Rachakatla R.S., Balivada S., Seo G.M., Myers C.B., Wang H., Samarakoon T.N., et al. Attenuation of mouse melanoma by a/c magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano 2010, 4:7093-7104.
17. Hadjipanayis C.G., Machaidze R., Kaluzova M., Wang L., Schuette A.J., Chen H., et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 2010, 70:6303-6312.
18. Gasche C., Berstad A., Befrits R., Beglinger C., Dignass A., Erichsen K., et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007, 13:1545-1553.
19. Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006, 21:378-382.
20. Yang J., Lee C.H., Ko H.J., Suh J.S., Yoon H.G., Lee K., et al. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed Engl 2007, 46:8836-8839.
21. Prutki M., Poljak-Blazi M., Mihaljevic B., Orescanin V., Zarkovic N. Uptake of anti-anemic substance ferric-sorbitol-citrate by normal and malignant cells and its effects on expression of transferrin receptor 1 and ferritin. Cancer Biother Radiopharm 2006, 21:636-644.
22. Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther 2011, 5:51-60.
23. Auerbach M., Rodgers G.M. Intravenous iron. N Engl J Med 2007, 357:93-94.
24. Steegmann-Olmedillas J.L. The role of iron in tumour cell proliferation. Clin Transl Oncol 2011, 13:71-76.
25. Richmond H.G. Induction of sarcoma in the rat by iron-dextran complex. Br Med J 1959, 1:947-949.
26. Weinbren K., Salm R., Greenberg G. Intramuscular injections of iron compounds and oncogenesis in man. Br Med J 1978, 1:683-685.
27. Foye L.V., Feichtmeir T.V. Massive and prolonged administration of iron-dextran complex. N Engl J Med 1961, 264:859-861.
28. Fu Y., Kraitchman D.L. Stem cell labeling for noninvasive delivery and tracking in cardiovascular regenerative therapy. Expert Rev Cardiovasc Ther 2010, 8:1149-1160.
29. Luciani A., Wilhelm C., Bruneval P., Cunin P., Autret G., Rahmouni A., et al. Magnetic targeting of iron-oxide-labeled fluorescent hepatoma cells to the liver. Eur Radiol 2009, 19:1087-1096.
30. Akiyama H., Ito A., Kawabe Y., Kamihira M. Genetically engineered angiogenic cell sheets using magnetic force-based gene delivery and tissue fabrication techniques. Biomaterials 2010, 31:1251-1259.
31. Srinivas M., Aarntzen E.H., Bulte J.W., Oyen W.J., Heerschap A., de Vries I.J., et al. Imaging of cellular therapies. Adv Drug Deliv Rev 2010, 62:1080-1093.
32. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
33. Budd G.T., Cristofanilli M., Ellis M.J., Stopeck A., Borden E., Miller M.C., et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403-6409.
34. Lubbe A.S., Bergemann C., Riess H., Schriever F., Reichardt P., Possinger K., et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 1996, 56:4686-4693.
35. Minamimura T., Sato H., Kasaoka S., Saito T., Ishizawa S., Takemori S., et al. Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats. Int J Oncol 2000, 16:1153-1158.
36. Lee J.S., Rodriguez-Luccioni H.L., Mendez J., Sood A.K., Lpez-Berestein G., Rinaldi C., et al. Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. J Nanosci Nanotechnol 2011, 11:4153-4157.